

Electronic Supplementary Information

For

Efficient iodine catalyzed three components domino reaction for the synthesis of 1-((phenylthio)(phenyl)methyl)pyrrolidin-2-one derivatives possessing anticancer activity

Gunasekar Ramachandran^a, Natesan Sundaramoorthy Karthikeyan^{a, b}, Periyasamy Giridharan^c, Kulathu Iyer Sathiyanarayanan^{a*}

^a*Chemistry Division, SAS, VIT University, Vellore-632014, Tamil Nadu, India.*

^b*Centre for Plastic Information Systems (CPIS), Department of Chemistry Education, Pusan National University, Busan - 609735, South Korea.*

^c*Primal Life Sciences Limited, Mumbai – 400063, India.*

sathiya_kuna@hotmail.com

Table of content

General experiment Method.....	4
Preparation of simulated gastric juice.....	4
General procedure for removal of fatty acids from serum albumin.....	4
Purification of Bovine serum albumin.....	4
Experimental procedure.....	5
Cell lines maintenance.....	5
Stability of the compound 4d using UV-Visible Spectra.....	6
Stability of the compound 4d using UV-Visible Spectra.....	7
Stability of the compound 4d using UV-Visible Spectra.....	8
Stability of the compound 4d using UV-Visible Spectra.....	9
Stability of the compound 4d using UV-Visible Spectra.....	10
Stability of the compound 4d using UV-Visible Spectra.....	11
Stability of the compound 4d using UV-Visible Spectra.....	12
Stability of the compound 4d using UV-Visible Spectra.....	13
Preliminary screening of pyrrolidones (4) for anticancer activity at 10 μ M concentration..	14
Preliminary screening of pyrrolidones (4) for anticancer activity at lower concentration... 1-((4-methoxyphenylthio)(phenyl)methyl)pyrrolidin-2-one (4a).....	15
1-((4-methoxyphenylthio)(phenyl)methyl)pyrrolidin-2-one (4a).....	17

1-((4-methoxyphenylthio)(o-tolyl)methyl)pyrrolidin-2-one (4b).....	19
1-((4-methoxyphenylthio)(p-tolyl)methyl)pyrrolidin-2-one (4c).....	21
1-((4-methoxyphenylthio)(2-methoxyphenyl)methyl)pyrrolidin-2-one (4d).....	23
1-((4-methoxyphenylthio)(4-methoxyphenyl)methyl)pyrrolidin-2-one (4e).....	25
1-((4-methoxyphenylthio)(4-chlorophenyl)methyl)pyrrolidin-2-one (4f).....	27
1-((4-methoxyphenylthio)(2-fluorophenyl)methyl)pyrrolidin-2-one (4g).....	29
1-((4-methoxyphenylthio)(2-ethoxyphenyl)methyl)pyrrolidin-2-one (4h).....	31
1-((4-methoxyphenylthio)(4-bromophenyl)methyl)pyrrolidin-2-one (4i).....	33
1-((4-methoxyphenylthio)(naphthalen-4-yl)methyl)pyrrolidin-2-one (4j).....	35
1,1'-(1,4-phenylenebis((4-methoxyphenylthio)methylene))dipyrrolidin-2-one (4k).....	37
1-((4-methoxyphenylthio)(4-(benzyloxy)phenyl)methyl)pyrrolidin-2-one (4l).....	39
1-((4-bromophenylthio)(phenyl)methyl)pyrrolidin-2-one (4m).....	41
1-((4-bromophenylthio)(4-chlorophenyl)methyl)pyrrolidin-2-one (4n).....	43
1-((4-bromophenylthio)(4-bromophenyl)methyl)pyrrolidin-2-one (4o).....	45
1-((4-bromophenylthio)(2-bromophenyl)methyl)pyrrolidin-2-one (4p).....	47
LC-Ms spectra of N-acyliminium intermediate from 2-Flurobenzaldehyde	49

GENERAL EXPERIMENT METHOD:

Chemicals were purchased from Aldrich and they were used without further purification. TLC -Thin layer chromatography (Merck, Silica gel 60 F254) was performed on pre-coated silica gel on alumina plates. IR spectra were recorded in the range 4000-400cm⁻¹ on Thermo Nicolet Avatar 330 FTIR spectrometer in KBr pellets. ¹H NMR and ¹³C NMR spectra were recorded using a Bruker AMX 400 FT. The X-ray crystallographic diffractions were determined using a Smart – CCD (Bruker, 2004).

PREPARATION OF SIMULATED GASTRIC JUICE

Simulated gastric juice was prepared using glucose (3.5 g/liter), NaCl (2.05 g/liter), KH₂PO₄(0.60 g/liter), CaCl₂(0.11 g/liter), and KCl (0.37 g/liter), adjusted to pH 2.0 using 1 M HCl, and autoclaved at 121°C for 15 min. Porcine bile (0.05 g/liter), lysozyme (0.1 g/liter), and pepsin (13.3 mg/liter) were added as stock solutions prior to analysis.

GENERAL PROCEDURE FOR REMOVAL OF FATTY ACIDS FROM SERUM ALBUMIN:

Albumin (7.0 g) was dissolved in 70 ml of Millipore water at 23". Darco (3.5 g) was mixed into the solution, and the pH was lowered to 3.0 by the addition of 0.2 N HCl. The solution was then placed in an ice bath and mixed magnetically for 1 hour. Charcoal was then removed by centrifugation at 20,200 for 20 min in a REMI cooling centrifuge at 2°C. The clarified solution was then brought to pH 7.0 by the addition of 0.2 N NaOH.

PURIFICATION OF BSA:

Bovine serum albumin which was free from fatty acid was used. BSA solutions (~40%) was prepared in 0.1 M KH₂PO₄ buffer, pH – 4.7. To it 0.1 % Norit suspension prepared in the

same buffer was slowly introduced and kept it for stirring at low speed in a magnetic stirrer for an hour at room temperature. The solution was filtered through Whatman filter paper \neq 1 and 0.2 Amicon filter under vacuum. After filtering successively, the BSA solution was adjusted to pH 7.4 with 5.0 M KOH. The BSA solution was lyophilized and kept for further use in cold.

EXPERIMENTAL PROCEDURE:


A dry 100ml Erlenmeyer flask was charged with γ -lactam (1.0 mmol); Aromatic aldehydes (1.0 mmol); Substituted thiophenol (1.0 mmol); Iodine (0.3 mmol) and DCM (15 ml). The reaction mixture was stirred at room temperature for 1-2 hrs. The reaction was monitored by TLC and after the completion of reaction iodine was liberated by treating it with aqueous sodium thiosulphate solution, extracted into DCM (2 X 20 ml) and the crude reaction mixture was purified by column chromatography on silica gel using ethylacetate/hexane as the eluents.

CELL LINE MAINTENANCE:

A panel of five cancer cells representing multiple cancers of clinical relevance were selected namely; ACHN (human renal cell, ATCC, CRL-1611), Panc-1 (human pancreatic, ATCC, CRL-1469) cultured on MEM with 2mM Lglutamine and 10% FBS, H460 (human non small cell lung carcinoma, ATCC, HTB- 177), Calu-1 (human lung carcinoma, ATCC, HTB-54) and MCF7 (human breast adenocarcinoma, ATCC HTB-22) cultured on RPMI, 2mM Lglutamine and 10% FBS, HCT-116 (human colon cancer, ATCC, CCL- 247) cultured on McCoy's 5a medium and 10% FBS and MCF10A (normal breast epithelium cells) cultured on MEM with 2mM L-glutamine and 10% FBS.

Stability of the compound using UV-Visible Spectra:


In SGF



Stability of 4b in SGF using UV spectra at specified time interval.


Concentration loss of 4b in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4b in BSA using UV-Visible spectra at specified time interval.


In SGF



Stability of 4f in SGF using UV spectra at specified time interval.


Concentration loss of 4f in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4f in BSA using UV- Visible spectra at specified time interval.


In SGF



Stability of 4g in SGF using UV spectra at specified time interval.


Concentration loss of 4g in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4g in BSA using UV- Visible spectra at specified time interval.


In SGF



Stability of 4i in SGF using UV spectra at specified time interval.


Concentration loss of 4i in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4i in BSA using UV-Visible spectra at specified time interval.


In SGF



Stability of 4j in SGF using UV spectra at specified time interval.


Concentration loss of 4j in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of the 4j in BSA using UV-Visible spectra at specified time interval.


In SGF



Stability of 4m in SGF using UV spectra at specified time interval.


Concentration loss of 4m in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4m in BSA using UV-Visible spectra at specified time interval.


In SGF



Stability of 4n in SGF using UV spectra at specified time interval.


Concentration loss of 4n in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4n in BSA using UV-Visible spectra at specified time interval.


In SGF



Stability of 4o in SGF using UV spectra at specified time interval.

Concentration loss of 4o in SGF using UV spectra at specified time interval.

In BSA



Concentration loss of 4o in BSA using UV-Visible spectra at specified time interval.

Table 5. Preliminary screening of pyrrolidones (4) for anticancer activity at 10 μM concentration.


Entry	code	Screening Concentration (in 10 μM)							HTS Remarks *
		ACHN (Renal Cancer)	Panc1 (Pancreatic cancer)	Calu1 (lung cancer)	H460 (Non small cell lung cancer)	HCT116 (Colon cancer)	MCF 7 (Breast cancer)	MCF10A (Normal breast epithelium cells)	
1	4a	33	32	30	31	35	21	10	NA
2	4b	94	97	92	99	95	87	59	A
3	4c	46	45	42	41	52	39	45	NA
4	4d	41	40	41	42	45	34	42	NA
5	4e	0	10	11	17	12	7	0	NA
6	4f	98	97	95	93	99	79	52	A
7	4g	83	80	79	85	82	84	49	A
8	4i	95	96	99	92	94	81	39	A
9	4o	99	98	99	97	92	86	58	A
10	4p	4	9	18	16	21	17	0	NA
11	4n	99	97	95	96	93	77	37	A
12	4m	99	96	99	98	97	82	52	A
13	4k	0	10	12	16	10	14	0	NA
14	4l	24	31	32	30	29	32	20	NA
15	4j	97	89	86	85	84	75	49	A
16	4h	47	37	38	38	42	23	40	NA
Positive Control 1-->Flavopiridol		88	81	89	80	87	77	21	A
Positive Control 2 -->Gemcitabine		79	88	82	80	75	81	12	A

* A - Active and NA - Not Active.


Table 6. Preliminary screening of pyrrolidones (4) for anticancer activity at lower concentration.


S.No	code	Screening conc. (μ M)	ACHN	Panc1	Calu1	H460	HCT116	MCF7 (Breast cancer)	MCF10A	HTS Remarks
1	4a	0.3	0	0	2	8	0	2	0	Not Active
		1	5	14	8	15	11	7	0	
		3	18	24	16	23	24	20	6	
2	4b	0.3	20	19	13	3	22	23	2	Active
		1	42	47	36	34	38	49	25	
		3	67	68	54	52	66	70	40	
3	4c	0.3	2	0	0	5	2	2	0	Not Active
		1	17	14	8	16	4	16	12	
		3	24	33	28	32	39	35	21	
4	4d	0.3	0	2	9	5	0	4	0	Not Active
		1	15	16	17	21	16	17	10	
		3	24	38	29	34	27	27	22	
5	4e	0.3	0	0	0	0	0	3	0	Not Active
		1	0	0	0	0	0	3	0	
		3	0	5	8	1	2	7	0	
6	4f	0.3	36	28	35	27	24	30	16	Active
		1	52	62	55	53	50	54	24	
		3	76	79	83	75	76	65	45	
7	4g	0.3	21	16	11	21	15	18	0	Active
		1	50	54	49	47	54	56	26	
		3	72	79	65	68	76	81	34	
8	4i	0.3	32	24	19	16	13	26	10	Active
		1	55	51	64	56	59	53	22	
		3	76	72	86	77	72	74	27	

9	4p	0.3	28	22	24	17	16	3	16	Active		
		1	70	66	56	53	53	3	24			
		3	84	83	87	68	87	85	43			
10	4o	0.3	0	0	0	0	0	2	0	Not Active		
		1	0	0	0	0	0	2	0			
		3	0	0	6	4	16	2	0			
11	4n	0.3	12	16	28	11	7	18	4	Active		
		1	48	44	47	32	29	47	18			
		3	64	75	63	59	52	45	26			
12	4m	0.3	16	8	4	6	7	2	0	Active		
		1	37	24	32	29	31	3	16			
		3	56	67	64	57	68	69	34			
13	4k	0.3	0	0	0	0	0	3	0	Not Active		
		1	0	0	0	0	0	3	0			
		3	2	4	1	7	6	5	0			
14	4l	0.3	5	2	0	0	8	3	0	Not Active		
		1	7	8	4	2	12	3	0			
		3	17	26	16	24	18	28	13			
15	4j	0.3	6	19	13	9	13	21	4	Active		
		1	18	33	26	20	24	35	16			
		3	50	53	49	44	56	35	32			
16	4h	0.3	5	0	0	5	2	3	0	Not Active		
		1	17	16	11	15	16	3	12			
		3	26	24	18	23	27	5	35			
Positive Control 1-->Flavopiridol 1000nM 88 81 89 80 87 73 21 Active												
Positive Control 2 -->Gemcitabine 1000nM 79 88 82 80 75 83 12 Active												




1-((4-methoxyphenylthio)(phenyl)methyl)pyrrolidin-2-one (4a): White crystalline Solid; mp 99-100 °C; R_f 0.45 (60% ethyl acetate : hexanes); FTIR (KBr) ν : 2946, 2885, 2831, 1689, 1585, 1488, 1453, 1403, 1349, 1248, 1171, 1016, 829 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): 1.83-1.88 (m, CH_2 , 2 H), 2.07-2.15(m, CH, 1 H), 2.20-2.27(m, CH, 1 H), 3.10-3.16(m, CH, 1 H), 3.72-3.76(m, CH, 1 H), 3.77(s, OCH_3 , 3 H), 6.78 (s, CH, 1 H), 6.82-6.85 (d, $J = 8.8$ Hz, 2 H), 7.31-7.47 (m, ArH, 7 H) ppm; ^{13}C NMR (100MHz, CDCl_3): 17.6, 30.9, 41.9, 55.2, 62.0, 114.6, 122.3, 128.8, 129.0, 134.3, 135.0, 135.6, 160.1, 174.6 ppm; HRMS: calculated for $\text{C}_{18}\text{H}_{19}\text{NO}_2\text{S} ([\text{M}]^+)$ 313.1136, Found 313.1136.







1-((4-methoxyphenylthio)(o-tolyl)methyl)pyrrolidin-2-one (4b): White crystalline Solid; mp 89-90 °C; R_f 0.46 (60% ethyl acetate : hexanes); FTIR (KBr) ν : 2937, 2881, 1689, 1587, 1486, 1405, 1347, 1251, 1171, 1019, 829 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.78-1.85 (m, CH₂, 2 H), 2.04-2.12 (m, CH, 1 H), 2.15-2.24 (m, CH, 1 H), 2.37 (s, CH₃, 3 H), 2.99-3.05 (m, CH, 1 H), 3.73-3.79 (m, CH, 1 H), 3.77 (s, OCH₃, 3 H), 6.82-6.84 (d, J = 8.4 Hz, 2 H), 6.89 (s, CH, 1 H), 7.16-7.65 (m, ArH, 6 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 19.6, 30.9, 42.0, 55.3, 59.9, 114.5, 122.8, 125.8, 127.8, 128.5, 130.9, 134.6, 136.2, 136.5, 160.1, 173.9 ppm; HRMS: calculated for C₁₉H₂₁NO₂S ([M]⁺) 327.1293, Found 327.1293.


BRUKER






1-((4-methoxyphenylthio)(p-tolyl)methyl)pyrrolidin-2-one (4c): White crystalline Solid; mp 108-109 °C; R_f 0.47 (60% ethyl acetate : hexanes); FTIR (KBr) : 2945, 2898, 1676, 1585, 1494, 1458, 1407, 1106, 1027, 818 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.80-1.88 (m, CH₂, 2 H), 2.07-2.15 (m, CH, 1 H), 2.21-2.31 (m, CH, 1 H), 2.34 (s, CH₃, 1 H), 3.10-3.16 (m, CH, 1 H), 3.71-3.76 (m, CH, 1 H), 3.78 (s, OCH₃, 3 H), 6.75 (s, CH, 1 H), 6.82-6.84 (d, *J* = 8.4 Hz, 2 H), 7.15-7.44 (m, ArH, 6 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 21.1, 31.0, 42.0, 55.3, 62.4, 114.5, 122.9, 129.3, 127.8, 133.4, 135.5, 138.3, 159.9, 174.6 ppm; HRMS: calculated for C₁₉H₂₁NO₂S ([M]⁺) 327.1293, Found 327.1293.






1-((4-methoxyphenylthio)(2-methoxyphenyl)methyl)pyrrolidin-2-one (4d): White crystalline Solid; mp 103-104 °C; R_f 0.42 (60% ethyl acetate : hexanes); FTIR (KBr) : 2963, 2891, 1694, 1590, 1487, 1401, 1101, 1024, 835 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.80-1.88 (m, CH₂, 2 H), 2.04-2.12 (m, CH, 1 H), 2.16-2.25 (m, CH, 1 H), 3.05-3.11 (m, CH, 1 H), 3.74-3.80 (m, CH, 1 H), 3.77 (s, OCH₃, 3 H), 3.82 (s, OCH₃, 3 H), 6.80-6.97 (m, ArH, 4 H), 7.11 (s, CH, 1 H), 7.26-7.61 (m, ArH, 4 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 31.0, 42.5, 55.2, 55.7, 57.0, 111.0, 114.4, 120.1, 123.2, 124.7, 129.0, 129.7, 136.1, 156.6, 159.9, 173.8 ppm; HRMS: calculated for C₁₉H₂₁NO₃S ([M]⁺) 343.1242, Found 343.1242.



BRUKER






1-((4-methoxyphenylthio)(4-methoxyphenyl)methyl)pyrrolidin-2-one (4e): White crystalline Solid; mp 102-103 °C; R_f 0.43 (60% ethyl acetate : hexanes); FTIR (KBr) : 2954, 2891, 1691, 1593, 1503, 1404, 1176, 1024, 826 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): 1.78-1.88 (m, CH_2 , 2 H), 2.05-2.14 (m, CH, 1 H), 2.19-2.28 (m, CH, 1 H), 3.15-3.16 (m, CH, 1 H), 3.72-3.76 (m, CH, 1 H), 3.78 (s, OCH_3 , 3 H), 3.80 (s, OCH_3 , 3 H), 6.73 (s, CH, 1 H), 6.82-6.89 (m, ArH, 4 H), 7.38-7.43 (m, ArH, 4 H) ppm; ^{13}C NMR (100MHz, CDCl_3): 17.6, 31.0, 42.0, 55.2, 62.1, 113.9, 114.5, 122.9, 128.5, 128.9, 132.6, 135.5, 159.6, 159.9, 174.5 ppm; HRMS: calculated for $\text{C}_{19}\text{H}_{21}\text{NO}_3\text{S} ([\text{M}]^+)$ 343.1242, Found 343.1243.



BRUKER







1-((4-methoxyphenylthio)(4-chlorophenyl)methyl)pyrrolidin-2-one (4f): White crystalline Solid; mp 111-112 °C; R_f 0.41 (60% ethyl acetate : hexanes); FTIR (KBr) : 2948, 2836, 1698, 1584, 1488, 1452, 1173, 1091, 1017, 823 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): 1.80-1.93 (m, CH_2 , 2 H), 2.07-2.11 (m, CH, 1 H), 2.13-2.29 (m, CH, 1 H), 3.06-3.12 (m, CH, 1 H), 3.69-3.75 (m, CH, 1 H), 3.78 (s, OCH_3 , 3 H), 6.73 (s, CH, 1 H), 6.82-6.85 (d, $J = 8.8 \text{ Hz}$, 2 H), 7.31-7.42 (m, ArH, 6 H) ppm; ^{13}C NMR (100MHz, CDCl_3): 17.6, 30.9, 41.9, 55.2, 62.0, 114.6, 122.3, 128.8, 129.0, 134.3, 135.0, 135.6, 160.1, 174.6 ppm; HRMS: calculated for $\text{C}_{18}\text{H}_{18}\text{ClNO}_2\text{S} ([\text{M}]^+)$ 347.0747, Found 347.0747.


BRUKER







1-((4-methoxyphenylthio)(2-fluorophenyl)methyl)pyrrolidin-2-one (4g): White crystalline Solid; mp 113-114 °C; R_f 0.44 (60% ethyl acetate : hexanes); FTIR (KBr) : 2973, 2887, 1691, 1586, 1487, 1450, 1178, 1093, 1024, 834 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.82-1.88 (m, CH₂, 2 H), 2.06-2.14 (m, CH, 1 H), 2.19-2.27 (m, CH, 1 H), 3.07-3.13 (m, CH, 1 H), 3.74-3.80 (m, CH, 1 H), 3.77 (s, OCH₃, 3 H), 6.82-6.84 (d, J = 8.8 Hz, 2 H), 7.00 (s, CH, 1 H), 7.03-7.65 (m, ArH, 6 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 30.8, 42.3, 55.2, 56.5, 114.5, 115.8, 122.4, 123.7, 123.8, 124.0, 129.4, 130.4, 136.0, 158.5, 160.2, 161.0, 174.0 ppm; HRMS: calculated for C₁₈H₁₈FNO₂S ([M]⁺) 331.1042, Found 331.1042.








1-((4-methoxyphenylthio)(2-ethoxyphenyl)methyl)pyrrolidin-2-one (4h): White crystalline Solid; mp 115-116 °C; R_f 0.43 (60% ethyl acetate : hexanes); FTIR (KBr) : 2977, 2878, 1697, 1590, 1489, 1457, 1173, 1020, 828 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): 1.38-1.42 (t, $J=14$ Hz, 3 H), 1.79-1.84 (m, CH_2 , 2 H), 2.04-2.10 (m, CH, 1 H), 2.12-2.23 (m, CH, 1 H), 3.04-3.10 (m, CH, 1 H), 3.69-3.75 (m, CH, 1 H), 3.77 (s, OCH_3 , 3 H), 4.00-4.04 (q, $J= 8.8$ Hz, 2 H), 6.81-6.95 (m, ArH, 4 H), 7.09 (s, CH, 1 H), 7.24-7.61 (m, ArH, 4 H) ppm; ^{13}C NMR (100MHz, CDCl_3): 14.7, 17.2, 31.0, 42.6, 55.2, 57.5, 64.0, 112.0, 114.3, 120.0, 123.4, 125.1, 129.0, 129.6, 135.9, 156.1, 159.8, 173.5 ppm; HRMS: calculated for $\text{C}_{20}\text{H}_{23}\text{NO}_3\text{S}$ ([M] $^+$) 357.1399, Found 357.1398.






1-((4-methoxyphenylthio)(4-bromophenyl)methyl)pyrrolidin-2-one (4i): White crystalline Solid; mp 126-127 °C; R_f 0.46 (60% ethyl acetate : hexanes); FTIR (KBr) : 2950, 2888, 1698, 1583, 1485, 1173, 1009, 827 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.84-1.91 (m, CH₂, 2 H), 2.07-2.15 (m, CH, 1 H), 2.21-2.95 (m, CH, 1 H), 3.06-3.12 (m, CH, 1 H), 3.68-3.74 (m, CH, 1 H), 3.78 (s, OCH₃, 3 H), 6.71 (s, CH, 1 H), 6.82-6.85 (d, J= 8.8 Hz, 2 H), 7.34-7.49 (m, ArH, 6 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 30.9, 41.9, 55.3, 62.1, 114.6, 122.5, 129.3, 131.8, 135.6, 160.1, 174.6 ppm; HRMS: calculated for C₁₈H₁₈BrNO₂S ([M] ⁺) 391.0242, Found 391.0242.







1-((4-methoxyphenylthio)(naphthalen-1-yl)methyl)pyrrolidin-2-one (4j): Light yellow crystalline Solid; mp 120-121 °C; R_f 0.48 (60% ethyl acetate : hexanes); FTIR (KBr) : 2964, 2830, 1686, 1588, 1491, 1182, 1026, 835 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.74-1.83 (m, CH₂, 2 H), 2.05-2.21 (m, CH, 2 H), 2.78-2.84 (m, CH, 1 H), 3.70-3.75 (m, CH, 1 H), 3.77 (s, OCH₃, 3 H), 6.84-6.86 (d, $J= 8$ Hz, 2 H), 7.44 (s, CH, 1 H), 7.45-8.24 (m, ArH, 9 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.4, 30.9, 41.8, 55.3, 59.7, 114.5, 122.5, 123.7, 124.8, 125.9, 126.1, 127.1, 128.6, 129.4, 131.0, 132.3, 133.8, 136.6, 160.3, 173.8 ppm; HRMS: calculated for C₂₂H₂₁NO₂S ([M]⁺) 363.1293, Found 363.1292.


BRUKER







1,1'-(1,4-phenylenebis((4-methoxyphenylthio)methylene))dipyrrolidin-2-one (4k): White Solid; mp 167-168 °C; R_f 0.51 (60% ethyl acetate : hexanes); FTIR (KBr) : 2945, 2836, 1688, 1587, 1493, 1173, 1025, 846 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.84-1.90 (m, CH₂, 4 H), 2.08-2.29 (m, CH, 4 H), 3.10-3.14 (m, CH, 2 H), 3.70-3.78 (m, CH, 2 H), 3.79 (s, OCH₃, 6 H), 6.76 (s, CH, 2 H), 6.83-6.85 (d, $J= 8\text{Hz}$, 4 H), 7.26-7.46 (m, ArH, 8 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 30.9, 42.0, 55.2, 62.3, 114.3, 114.6, 122.5, 127.9, 135.5, 136.7, 160.0, 174.6 ppm; HRMS: calculated for C₃₀H₃₂N₂O₄S₂ ([M]⁺) 548.1803, Found 548.1802.






1-((4-methoxyphenylthio)(4-(benzyloxy)phenyl)methyl)pyrrolidin-2-one (4l): White Solid; mp 105-106 °C; R_f 0.42 (60% ethyl acetate : hexanes); FTIR (KBr) : 2942, 2836, 1691, 1592, 1498, 1171, 1009, 830 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.63-1.90 (m, CH₂, 2 H), 2.08-2.28 (m, CH₂, 2 H), 3.11-3.17 (m, CH, 2 H), 3.70-3.77 (m, CH, 2 H), 3.78 (s, OCH₃, 3 H), 6.73 (s, CH, 1 H), 6.82-6.84 (d, *J*= 8.8Hz, 2 H), 6.94-6.96 (d, *J*= 8.8Hz, 2 H), 7.32-7.43 (m, ArH, 8 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 31.0, 41.9, 55.2, 62.1, 70.0, 114.5, 114.8, 122.9, 127.4, 128.0, 128.6, 128.8, 128.9, 135.6, 136.7, 158.8, 159.9, 174.5 ppm; HRMS: calculated for C₂₅H₂₅NO₃S ([M]⁺) 419.1555, Found 419.1556.






1-((4-bromophenylthio)(phenyl)methyl)pyrrolidin-2-one (4m): White Crystal; mp 100-101 °C; R_f 0.49 (60% ethyl acetate : hexanes); FTIR (KBr) : 2937, 2877, 1688, 1457, 1226, 1076, 821 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.82-1.86 (m, CH₂, 2 H), 2.18-2.22 (m, CH₂, 2 H), 2.25-2.29 (m, CH₂, 2 H), 3.15-3.19 (m, CH, 1 H), 3.61-3.66 (m, CH, 1 H), 6.91 (s, CH, 1 H), 7.32-7.47 (m, ArH, 9 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.6, 31.0, 42.2, 61.4, 122.0, 127.4, 128.7, 128.8, 131.9, 132.1, 133.6, 135.9, 174.8 ppm; HRMS: calculated for C₁₇H₁₆BrNOS ([M]⁺) 361.0136, Found 361.0137.


BRUKER







1-((4-bromophenylthio)(4-chlorophenyl)methyl)pyrrolidin-2-one 4n: White Solid; mp 119-120 °C; R_f 0.56 (60% ethyl acetate : hexanes); FTIR (KBr) : 2962, 2879, 1684, 1478, 1404, 1184, 1080, 817 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.78-1.93 (m, CH₂, 2 H), 2.13-2.33 (m, CH, 1 H), 3.09-3.14 (m, CH, 1 H), 3.58-3.64 (m, CH, 1 H), 6.87 (s, CH, 1 H), 7.31-7.43 (m, ArH, 8 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.7, 30.9, 42.1, 60.7, 122.2, 128.8, 129.0, 131.5, 132.2, 133.7, 134.5, 134.6, 174.8 ppm; HRMS: calculated for C₁₇H₁₅BrClNOS ([M]⁺) 394.9746, Found 394.9747


BRUKER







1-((4-bromophenylthio)(2-bromophenyl)methyl)pyrrolidin-2-one (4o): White Solid; mp 121-122 °C; R_f 0.42 (60% ethyl acetate : hexanes); FTIR (KBr) : 2952, 2901, 1685, 1546, 1490, 1111, 1034, 859 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.84-1.91 (m, CH₂, 2 H), 2.14-2.31 (m, CH, 2 H), 3.10-3.15 (m, CH, 1 H), 3.59-3.63 (m, CH, 1 H), 6.85 (s, CH, 1 H), 7.31-7.51 (m, ArH, 8 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.71, 30.89, 42.12, 60.89, 122.23, 122.78, 129.18, 131.50, 131.97, 132.20, 133.74, 135.08, 174.79 ppm; HRMS: calculated for C₁₇H₁₅Br₂NOS ([M]⁺) 438.9241, Found 438.9240.





1-((4-bromophenylthio)(4-bromophenyl)methyl)pyrrolidin-2-one (4p): White Solid; mp 131-132 °C; R_f 0.41 (60% ethyl acetate : hexanes); FTIR (KBr) : 2966, 2879, 1685, 1552, 1475, 1184, 1086, 816 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): 1.85-1.96 (m, CH₂, 2 H), 2.13-2.37 (m, CH, 2 H), 3.10-3.18 (m, CH, 1 H), 3.59-3.67 (m, CH, 1 H), 6.86 (s, CH, 1 H), 7.28-7.53 (m, ArH, 8 H) ppm; ¹³C NMR (100MHz, CDCl₃): 17.7, 30.9, 42.1, 60.8, 122.2, 122.8, 129.1, 131.4, 131.9, 132.2, 133.7, 135.0, 174.8 ppm; HRMS: calculated for C₁₇H₁₅Br₂NOS ([M]⁺) 438.9241, Found 438.9241.




LC-Ms spectra of N-acyliminium intermediate from 2-Flurobenzaldehyde

Data File C:\CHEM32\1\DATA\LAB-2\R11000007.D
Sample Name: r11

```
=====
Acq. Operator   : sandeep
Acq. Instrument : Instrument 1                     Location : Vial 1
Injection Date  : 3/22/2012 6:16:36 PM                 Inj : 1
                                         Inj Volume : 5.000 µl
Acq. Method     : C:\CHEM32\1\METHODS\BASIC COMPOUND .M
Last changed    : 3/22/2012 6:15:30 PM by sandeep
                  (modified after loading)
Analysis Method  : C:\CHEM32\1\METHODS\BASIC COMPOUND .M
Last changed    : 3/22/2012 6:42:24 PM by narayan
Method Info     : acidicic
```

Sample-related custom fields:

Name	Value
Additional Info	: Peak(s) manually integrated




Sample-related custom fields:

Name	Value
Additional Info	: Peak(s) manually integrated

MS Signal: MSD1 TIC, MS File, MM-ES+APCI, Pos, Scan, Frag: 140, "Pos ES"
Spectra averaged over upper half of peaks.
Noise Cutoff: 500 counts.
Reportable Ion Abundance: > 10%.

Retention Time (MS)	MS Area	Mol. Weight or Ion
5.029	12455172	191.80 I
		163.85 I
		148.90 I
		123.90 I



*** End of Report ***